Get the Stockscreener App
0.8179
0.99%
0.008
After Hours:
.75
-0.0679
-8.30%
Lunai Bioworks Inc stock is traded at $0.8179, with a volume of 101.89K.
It is up +0.99% in the last 24 hours and down -13.29% over the past month.
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.
See More
Previous Close:
$0.8099
Open:
$0.87
24h Volume:
101.89K
Relative Volume:
0.09
Market Cap:
$19.16M
Revenue:
-
Net Income/Loss:
$-178.01M
P/E Ratio:
-0.0982
EPS:
-8.326
Net Cash Flow:
$-7.87M
1W Performance:
+26.43%
1M Performance:
-13.29%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.80
$0.92
1-Week Range:
$0.63
$1.115
52-Week Range:
$0.63
$1.66
Lunai Bioworks Inc Stock (LNAI) Company Profile
Name
Lunai Bioworks Inc
Sector
Industry
Phone
45 39179840
Address
CENTURY CITY MEDICAL PLAZA, SUITE 906 LOS ANGELES
Compare LNAI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LNAI
Lunai Bioworks Inc
|
0.8179 | 18.98M | 0 | -178.01M | -7.87M | -8.326 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Lunai Bioworks Inc Stock (LNAI) Latest News
Lunai Bioworks Faces Nasdaq Delisting After Bid Price Breach - TipRanks
Lunai Bioworks, Inc. Issues Letter to Shareholders - The Malaysian Reserve
LNAI Partners on Phase 2 Cancer Trial to Enhance Patient Outcomes - GuruFocus
LNAI Strengthens AI Platform for Biotech Innovations and Partner - GuruFocus
Lunai Bioworks (NASDAQ: LNAI) Launches AI Oncology Pilot with Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial Data - Finviz
Lunai Bioworks (Nasdaq LNAI) launches AI oncology pilot - marketscreener.com
Lunai Bioworks (Nasdaq Lnai) Launches Ai Oncology Pilot - TradingView
Lunai Bioworks launches AI analysis of colorectal cancer trial data - Investing.com
Lunai Bioworks Launches AI Oncology Pilot with Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial Data - marketscreener.com
Lunai Bioworks (NASDAQ: LNAI) Launches Sentinel, an AI Safeguard to Block Large Language Models from Generating Novel Chemical Weapons - Finviz
Lunai Bioworks Highlights Sentinel AI Safeguard After Anthropic CEO Warning on AI Chemical and Biological Threats - natlawreview.com
Lunai Launches Sentinel AI Biosecurity Layer - Intellectia AI
AI safeguard Sentinel blocks novel chemical weapon designs at source - stocktitan.net
Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use Disorder Drug Discovery - The Malaysian Reserve
Lunai Bioworks launches alcohol use disorder drug discovery program By Investing.com - Investing.com Canada
Lunai Bioworks Expands NIH-Backed AI Platform Into Commercial Alcohol Use Disorder Drug Discovery - Nasdaq
LNAI Advances Drug Discovery Program for Alcohol Use Disorder - GuruFocus
Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into - GuruFocus
Lunai Bioworks Launches Alcohol Use Disorder Program Following Key Milestones - Intellectia AI
Lunai Bioworks Inc. Unveils Transformer Platform to Secure Generative AI and Accelerate Drug Discovery - Montgomery Advertiser
Lunai Bioworks : JP Morgan Healthcare ConferenceMedTech Showcase Presentation - marketscreener.com
Lunai Bioworks (NASDAQ:LNAI) Raised to “Hold” at Wall Street Zen - Defense World
Lunai Bioworks (NASDAQ: LNAI) Featured in International Business Times as AI Partnership Talks Advance - GuruFocus
AI drug startup in Parkinson's race draws attention as pharma talks heat up - Stock Titan
Lunai Bioworks: Year-End Partnering Momentum & Stock Setup - International Business Times
Lunai bioworks identifies three parkinsons disease subtypes By Investing.com - Investing.com South Africa
Lunai bioworks identifies three parkinsons disease subtypes - Investing.com
Lunai Bioworks identifies three Parkinson's disease subtypes - marketscreener.com
Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market - Barchart.com
Ready to Jump After Recent Trade: Lunai Bioworks Inc (LNAI) - setenews.com
Lunai Bioworks to effect 10:1 reverse stock split - MSN
Lunai Bioworks (LNAI) Stock Analysis Report | Financials & Insights - Benzinga
Lunai Bioworks enters sales agreement with Dawson James SecuritiesSEC filing - marketscreener.com
Lunai Bioworks Enters Sales Agreement with Dawson James - TipRanks
Does Lunai Bioworks Inc (LNAI) offer a good opportunity for investors? - Setenews
Lunai Bioworks’ immune cell therapy shows tumor regression, wins first license - MSN
Lunai Bioworks stock soars after securing first licensing deal for cancer therapy - MSN
Lunai Bioworks - The Pharma Letter
Lunai Bioworks lands first licensing deal for off-the-shelf cancer immunotherapy - The Pharma Letter
There is no way Lunai Bioworks Inc (LNAI) can keep these numbers up - Setenews
Lunai Bioworks Secures $3.1M in Private Placement - The Globe and Mail
Lunai Bioworks Inc (2Q50.MU) latest stock news and headlines - Yahoo Finance Australia
Lunai Bioworks Inc. (LNAI) -7.5% in After-hours: Shares Decline Amidst New Licensing Agreement - Stocks Telegraph
Lunai Bioworks sells 3,133,333 shares in private financing deal - Stock Titan
LNAI Stock: Surging or Slipping? - StocksToTrade
Lunai Bioworks (LNAI) Stock: Plummets 14.2% Despite Breakthrough in Cancer Immunotherapy - parameter.io
Lunai Bioworks Shares Rise After Company Secures Licensing Intent for Dendritic Cell Therapy - marketscreener.com
Lunai Bioworks: Stock Surge or Bubble? - timothysykes.com
Lunai Bioworks stock soars after securing first licensing deal for cancer therapy By Investing.com - Investing.com South Africa
LNAI's Groundbreaking Immune Cell Therapy Advances with Key Lice - GuruFocus
Lunai Bioworks Secures First Licensing LOI Following Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models - MarketScreener
Lunai Bioworks Inc Stock (LNAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):